We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Improving on "Natural" Rodent Antibodies
-
1. The immunogenicity problem in antibody therapy
- Prof. Herman Waldmann
-
2. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
3. Bispecific and multispecific antibodies in biotherapeutic drug design
- Prof. Paul Parren
- Antibodies in Cancer Therapy
-
4. Monoclonal antibodies and the ErbB system in human cancer
- Prof. Mark Greene
-
5. Monoclonal antibodies in haemato-oncology
- Prof. Mark Cragg
- Diagnostic Antibodies
-
6. Monitoring therapy with antibodies
- Dr. Geoffrey Hale
- Cell Surface Glycoproteins on Cells of the Immune System
-
7. Cell surface glycoproteins on cells of the immune system
- Prof. Neil Barclay
- Antibodies as Immunosuppressants
-
8. Monoclonal antibodies to induce therapeutic immunological tolerance
- Prof. Herman Waldmann
-
9. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
10. Monoclonal antibodies in the management of rheumatoid arthritis
- Prof. John Isaacs
-
13. Antibodies as taught by viral pathogens, especially HIV
- Prof. Dennis Burton
- Archived Lectures *These may not cover the latest advances in the field
-
14. Alemtuzumab (Campath-1H) in therapy of CLL
- Prof. Kanti Rai
-
15. VEGF inhibitors for anti-angiogenic therapy
- Prof. Kari Alitalo
- Dr. Bronislaw Pytowski
-
16. Human antibodies produced in mice
- Dr. Marianne Bruggemann
-
17. New strategies to prevent transplant rejection: from molecules to mice to monkeys to man
- Prof. Christian Larsen
-
18. CD20 antibodies in the targeting of B-cell malignancies and autoimmunity
- Prof. Thomas Tedder
-
19. Anti-IL-2 receptor antibodies as models for cancer therapy
- Prof. Thomas Waldmann
-
20. Anti TNF therapy in rheumatoid arthritis
- Prof. Marc Feldmann
-
21. Novel immunotherapeutic proteins: immunoligand
- Prof. Terry Strom
-
22. Diagnostic immunohistopathology
- Prof. David Mason
-
23. Antibodies in the control of type I diabetes
- Prof. Lucienne Chatenoud
-
24. The challenge of targeting toxins to tumors
- Prof. Ben Seon
-
25. Antibody depletion therapy in transplantation: implications for tolerance
- Prof. Laurence Turka
-
26. Antibodies by protein engineering
- Prof. Sir Gregory Winter
-
27. Antibody therapy of multiple sclerosis
- Dr. Alasdair Coles
- Prof. Alastair Compston
-
28. The generation of diversity in antibody genes
- Prof. Michael Neuberger
-
29. Innate immunity to retroelements by human AID/APOBEC3 proteins
- Prof. Reuben Harris
-
30. Fc receptors and antibody effector functions
- Dr. Mike Clark
-
31. Antibody engineering of Fc effector functions
- Dr. Mike Clark
-
32. Checkpoint blockade in cancer immunotherapy
- Prof. James Allison
-
33. Antibodies as anti-virals
- Prof. Dennis Burton
Printable Handouts
Navigable Slide Index
- Introduction
- Antibodies to pathogens: the generations
- Super-antibodies against viruses
- Generation of mAbs to pathogens
- 1976 Nobel Prize for monoclonal antibodies
- Hybridoma technology to generate mAbs
- Human mAb generation from the early 90s
- mAb generation from human immune donors: single B cells
- Approaches for the discovery of rare super-antibodies using single B cells
- bnAbs against highly variable viruses
- Some lessons from super-antibodies
- Anti-viral antibodies in vitro and in vivo
- Neutralization: in vitro assay
- Mechanisms of neutralization
- Size of antibody molecules is often underestimated
- Antibody-mediated neutralization of HIV
- Neutralizing antibody (nAb) anti-viral activity including Ab effector functions
- Passive antibody protection against HIV
- bnAb (b12) protection against SHIV challenge in NHPs
- Passive bnAb protection vs. neutralization
- Correlation between neutralization and protection
- The Antibody Mediated Prevention study results
- Comparison of passive nAb protection in SHIV/macaque and in HIV/humans
- Common themes associated with nAb functions in vivo
- Anti-viral antibodies and effector function
- Effector function in antibody protection against HIV
- Model of tripartite interaction of FcR, Ab & viral spike
- HIV and super-antibodies
- The HIV Env spike: sole target of nAbs
- HIV Env spike: an extremely difficult antibody target
- bnAb PGT145 penetrates the glycan shield of HIV Env
- In vivo activity of bnAbs: PGT121
- Super-antibodies and animal repertoires
- nAb responses to HIV Env trimer immunization
- Cows can make bnAbs by Env immunization
- Super-antibodies and vaccines
- Reverse vaccinology 2.0
- Reverse vaccinology 2.0/Ab-guided structure-based vaccine design
- Towards an HIV vaccine
- From naïve Abs to bnAbs: a vaccine strategy
- Sequential immunization strategy to induce bnAbs (1)
- bnAb sites for vaccine targeting
- eOD-GT8 60mer Phase 1 trial (IAVI G001)
- IAVI G001-G003 major conclusions
- Sequential immunization strategy to induce bnAbs (2)
- Conclusions
- Thank you and financial disclosures
Topics Covered
- Monoclonal antibody generation
- Hybridoma technology
- Super antibodies
- Broadly neutralizing antibody (bnAbs)
- Antiviral antibodies and effector function
- HIV envelope spikes
- Reverse vaccinology
- Sequential immunization strategy for bnAbs
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Burton, D. (2026, January 28). Antibodies as taught by viral pathogens, especially HIV [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved June 25, 2026, from https://doi.org/10.69645/WRNA9814.Export Citation (RIS)
Publication History
- Published on January 28, 2026
Financial Disclosures
- There are no commercial/financial matters to disclose.
A selection of talks on Immunology
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Dennis Burton
from Scripps Research
Institute in La Jolla,
California, United States.
I'd like to talk
about antibodies
as taught by viral
pathogens, especially HIV.
What I mean by that
is that we've spent
a lot of time studying the
interplay of antibodies
and this highly
mutating virus, HIV.
I think we've learned quite
a lot about antibodies
that we did not necessarily know
or fully realize previously.
0:39
I consider that, in terms
of antibodies to pathogens,
there have been a
number of generations
and we're now, I would argue,
on the fourth generation.
The first generation was
immune sera against
bacterial toxins,
particularly
diphtheria, tetanus,
that was used to treat
bacterial diseases,
and this earned the
very first Nobel Prize
in Medicine and Physiology
for von Behring,
and subsequent generations have
led to greater refinement,
in terms of the
antibody preparations.
The second generation was
polyclonal antibody preparations
that were very successfully
used for viral prophylaxis.
For example, against
hepatitis B,
respiratory syncytial virus,
and, importantly,
post-exposure prophylaxis,
e.g., against rabies.
Then further refinement.
The third generation was
monoclonal antibodies,
and these, of course,
first in mouse,
then humanized mouse antibodies,
and then fully human antibodies.
They've been used for
a wide range of
therapeutic applications,
including viral prophylaxis,
where the signature antibody
was against RSV-Synagis.
Now, I think we have arrived
at the fourth generation,
which we have termed
super-antibodies,
which are monoclonal antibodies
of quite outstanding potency
and/or cross-reactivity.
We give them a nomination
as a new generation.
They can do things that, say,
regular monoclonal
antibodies could not,
so we consider them to be
a considerable advance.